

# PARAGON-HF

#ESCCongress



AMERICAN  
COLLEGE of  
CARDIOLOGY®

**Trial Description:** Patients with heart failure with preserved ejection fraction were randomized to sacubitril-valsartan 97/103 mg twice daily versus valsartan 160 mg twice daily.

## RESULTS

- Primary efficacy endpoint: rate of cardiovascular deaths or hospitalizations for heart failure was 12.8 events per 100 patient-years in the sacubitril-valsartan group vs. 14.6 events per 100 patient-years in the valsartan group (p = NS)
- NYHA class improvement: 15.0% in the sacubitril-valsartan group vs. 12.6% in the valsartan group (p < 0.05)

## CONCLUSIONS

- Among patients with heart failure with preserved ejection fraction, sacubitril-valsartan was not effective at reducing the incidence of cardiovascular death or hospitalization for heart failure compared with valsartan

Solomon SD, et al. N Engl J Med 2019;Sep 1:[Epub]

